Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance

Female,Scientist,Working,In,The,Lab,,She,Is,Wearing,A

Telix Pharmaceuticals (NASDAQ:TLX) updated on Tuesday its commercial and operational performance for the third quarter of fiscal 2025.

Telix reported third-quarter revenue of $206 million, up 53% year over year and 1% sequentially. PSMA imaging revenue increased 17% to $155 million, and RLS third-party revenue reached $47 million.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.